Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (151-160 of 179) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 18, 2022
mCRPC Patients Receiving <sup>225</sup>Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival AnalysisMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Angewandte Chemie (International Ed. in English)|June 25, 2010
[An(H2O)9](CF3SO3)3 (An=U-Cm, Cf): exploring their stability, structural chemistry, and magnetic behavior by experiment and theoryChristos Apostolidis, Bernd Schimmelpfennig, Nicola Magnani, et al.
The Prostate|September 7, 2006
Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugatesJian Wang, Syed M Abbas Rizvi, Michele C Madigan, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma ModelRobin I J Merkx, Mark Rijpkema, Gerben M Franssen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2017
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer XenograftsSandra Heskamp, Reinier Hernandez, Janneke D M Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical TherapyJulie Constanzo, Aliasghar Parach, Timothee David, et al.
Molecular Pharmaceutics|August 14, 2020
Therapeutic Efficacy of <sup>213</sup>Bi-labeled sdAbs in a Preclinical Model of Ovarian CancerYana Dekempeneer, Vicky Caveliers, Maarten Ooms, et al.
Oncoimmunology|November 15, 2021
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple MyelomaKim De Veirman, Janik Puttemans, Ahmet Krasniqi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2019
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated GenesClemens Kratochwil, Frederik L Giesel, Claus-Peter Heussel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2018
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot studyMichael E Autenrieth, Christof Seidl, Frank Bruchertseifer, et al.
Pageof 18

Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 18, 2022
mCRPC Patients Receiving <sup>225</sup>Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival AnalysisMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Angewandte Chemie (International Ed. in English)|June 25, 2010
[An(H2O)9](CF3SO3)3 (An=U-Cm, Cf): exploring their stability, structural chemistry, and magnetic behavior by experiment and theoryChristos Apostolidis, Bernd Schimmelpfennig, Nicola Magnani, et al.
The Prostate|September 7, 2006
Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugatesJian Wang, Syed M Abbas Rizvi, Michele C Madigan, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma ModelRobin I J Merkx, Mark Rijpkema, Gerben M Franssen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2017
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer XenograftsSandra Heskamp, Reinier Hernandez, Janneke D M Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical TherapyJulie Constanzo, Aliasghar Parach, Timothee David, et al.
Molecular Pharmaceutics|August 14, 2020
Therapeutic Efficacy of <sup>213</sup>Bi-labeled sdAbs in a Preclinical Model of Ovarian CancerYana Dekempeneer, Vicky Caveliers, Maarten Ooms, et al.
Oncoimmunology|November 15, 2021
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple MyelomaKim De Veirman, Janik Puttemans, Ahmet Krasniqi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2019
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated GenesClemens Kratochwil, Frederik L Giesel, Claus-Peter Heussel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2018
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot studyMichael E Autenrieth, Christof Seidl, Frank Bruchertseifer, et al.
Pageof 18